Autosomal Dominant Polycystic Kidney Disease Market to Grow Positively at a Paltry CAGR During the Study Period | Otsuka Pharmaceutical, Sanofi, Regulus Therapeutics, and others

DelveInsight's "Autosomal Dominant Polycystic Kidney Disease - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Autosomal Dominant Polycystic Kidney Disease market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease market size from 2020 to 2034 segmented by seven major markets. The report also offers current Autosomal Dominant Polycystic Kidney Disease therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autosomal Dominant Polycystic Kidney Disease market.
Download sample report @ https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key facts from the Autosomal Dominant Polycystic Kidney Disease Market report:
The Autosomal Dominant Polycystic Kidney Disease Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
The continual increase in autosomal dominant polycystic kidney disease diagnosed cases, driven by technological advancements facilitating early detection, presents a fertile ground for the introduction of novel therapies in the autosomal dominant polycystic kidney disease market. Furthermore, ongoing progress in understanding the genetic underpinnings, non-invasive monitoring, and prognostication of autosomal dominant polycystic kidney disease promises enhanced disease management, with pre-symptomatic diagnosis offering further avenues for patient care optimization.
With limited US FDA-approved therapies, there is an opportunity for key players to introduce disease-modifying therapies addressing the root causes of cyst formation and kidney deterioration for autosomal dominant polycystic kidney disease.
There is a profound effect of autosomal dominant polycystic kidney disease on patients' well-being, citing chronic pain, kidney impairment, and related health issues. They underscore the necessity of addressing both the physical manifestations and the psychological toll of enduring a chronic, advancing condition.
Autosomal Dominant Polycystic Kidney Disease Overview
Autosomal dominant polycystic kidney disease (ADPKD), also known as "adult PKD," is the most common inherited kidney disorder. It is marked by the development of cysts in the kidneys, which can eventually lead to kidney failure. This monogenic disorder is caused by mutations in either the PKD1 gene on chromosome 16 or the PKD2 gene on chromosome 4, with mutations in PKD1 being more prevalent and responsible for about 85% of ADPKD cases.

ADPKD is characterized by bilateral kidney cysts, kidney pain, frequent urinary tract infections, hematuria, nephrolithiasis, hypertension, and progressive renal failure due to cyst enlargement and fibrosis. It is a leading cause of renal replacement therapy and end-stage renal disease.

Diagnosis of Autosomal Dominant Polycystic Kidney Disease

Diagnosing ADPKD typically involves a comprehensive approach, including evaluating symptoms, conducting imaging tests, genetic analysis, and reviewing family medical history. Urine tests are used to detect blood or protein, while imaging techniques such as ultrasound help visualize kidney abnormalities. Additionally, glomerular filtration rate (GFR) testing may be performed to assess kidney function. This thorough diagnostic process aims to accurately identify ADPKD, enabling timely intervention and effective management.
To know more about ADPKD, treatment landscape, visit: https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autosomal Dominant Polycystic Kidney Disease Epidemiological Insights
As per DeveInsight analysis, in 2023, the total autosomal dominant polycystic kidney disease diagnosed prevalent cases of in the 7MM were found to be approximately 194,251 cases. These cases are likely to change by 2034 in the forecast period 2024-2034.
The US accounted for approximately 144,697 autosomal dominant polycystic kidney disease diagnosed prevalent cases in the year 2023. These cases are expected to increase driven by the increasing occurrence of kidney disorders due to obesity and hypertension in the US.
In 2023, among the EU4 and the UK, the UK accounted for the highest number of autosomal dominant polycystic kidney disease diagnosed prevalent cases with approximately 68,138 cases followed by France at 61,676. In contrast, Italy with nearly 16,476 cases accounts for the lowest number of cases.
In the US, the age-specific cases of

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.